Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH.

Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.

PMID:
29807781
2.

Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.

Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M, Kuzel TM.

Eur Urol. 2018 May;73(5):648-652. doi: 10.1016/j.eururo.2017.12.008. Epub 2017 Dec 21. Review.

PMID:
29275833
3.

Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.

Pu H, Collazo J, Jones E, Gayheart D, Sakamoto S, Vogt A, Mitchell B, Kyprianou N.

Cancer Res. 2009 Sep 15;69(18):7366-74. doi: 10.1158/0008-5472.CAN-09-0758. Epub 2009 Sep 8.

4.

Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.

Hassani M, Hajari Taheri F, Sharifzadeh Z, Arashkia A, Hadjati J, van Weerden WM, Modarressi MH, Abolhassani M.

J Cell Biochem. 2019 Jun;120(6):10787-10795. doi: 10.1002/jcb.28370. Epub 2019 Jan 22.

PMID:
30672018
5.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, Larson SM, Koutcher JA, Sadelain M.

Cancer Res. 2005 Oct 1;65(19):9080-8.

6.

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.

Ma Q, Gomes EM, Lo AS, Junghans RP.

Prostate. 2014 Feb;74(3):286-96. doi: 10.1002/pros.22749.

PMID:
24174378
7.

Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse.

Ando Y, Yang GX, Kenny TP, Kawata K, Zhang W, Huang W, Leung PS, Lian ZX, Okazaki K, Ansari AA, He XS, Invernizzi P, Ridgway WM, Lu Q, Gershwin ME.

J Autoimmun. 2013 Mar;41:111-9. doi: 10.1016/j.jaut.2012.12.013. Epub 2013 Feb 8.

8.

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Hillerdal V, Essand M.

BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. Review.

9.

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.

Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM.

J Immunother. 2008 Jun;31(5):500-5. doi: 10.1097/CJI.0b013e318177092b.

10.

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.

Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ.

Oncoimmunology. 2017 Oct 16;7(2):e1380764. doi: 10.1080/2162402X.2017.1380764. eCollection 2018.

11.

Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-β signaling in CD8+ T lymphocytes.

Papadakis KA, Krempski J, Reiter J, Svingen P, Xiong Y, Sarmento OF, Huseby A, Johnson AJ, Lomberk GA, Urrutia RA, Faubion WA.

Am J Physiol Cell Physiol. 2015 Mar 1;308(5):C362-71. doi: 10.1152/ajpcell.00262.2014. Epub 2014 Dec 3.

12.

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.

Serganova I, Moroz E, Cohen I, Moroz M, Mane M, Zurita J, Shenker L, Ponomarev V, Blasberg R.

Mol Ther Oncolytics. 2016 Dec 14;4:41-54. doi: 10.1016/j.omto.2016.11.005. eCollection 2017 Mar 17.

13.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

14.

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Bollard CM, Rössig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM.

Blood. 2002 May 1;99(9):3179-87.

15.

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ.

Oncoimmunology. 2015 Jan 23;4(3):e994446. eCollection 2015 Mar.

16.

TGF-β-responsive CAR-T cells promote anti-tumor immune function.

Hou AJ, Chang ZL, Lorenzini MH, Zah E, Chen YY.

Bioeng Transl Med. 2018 Jul 27;3(2):75-86. doi: 10.1002/btm2.10097. eCollection 2018 May.

17.

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.

Chen C, Li K, Jiang H, Song F, Gao H, Pan X, Shi B, Bi Y, Wang H, Wang H, Li Z.

Cancer Immunol Immunother. 2017 Apr;66(4):475-489. doi: 10.1007/s00262-016-1949-8. Epub 2016 Dec 29.

PMID:
28035433
18.

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.

Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C.

Mol Cancer Ther. 2006 Jul;5(7):1733-43.

19.

Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.

Zuo S, Wen Y, Panha H, Dai G, Wang L, Ren X, Fu K.

Mol Immunol. 2017 May;85:293-304. doi: 10.1016/j.molimm.2017.03.017. Epub 2017 Mar 27.

PMID:
28360017
20.

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.

Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF.

Mol Ther. 2017 Jan 4;25(1):249-258. doi: 10.1016/j.ymthe.2016.10.016. Epub 2017 Jan 4.

Supplemental Content

Support Center